BRAF in metastatic colorectal cancer: the future starts now

被引：14

作者：

Orlandi, Armando ^{[1
]}

Calegari, Maria Alessandra ^{[1
]}

Inno, Alessandro ^{[2
]}

Berenato, Rosa ^{[3
]}

Caporale, Marta ^{[3
]}

Niger, Monica ^{[3
]}

Bossi, Ilaria ^{[3
]}

Di Bartolomeo, Maria ^{[3
]}

de Braud, Filippo ^{[3
]}

Pietrantonio, Filippo ^{[3
]}

机构：

[1] Univ Cattolica Sacro Cuore, Dept Med Oncol, Rome, Italy

[2] Sacro Cuore Don Calabria Hosp, Med Oncol, Verona, Italy

[3] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy

来源：

PHARMACOGENOMICS | 2015年 / 16卷 / 18期

关键词：

BRAF; colorectal cancer; immunotherapy; target therapy; FOLFOXIRI PLUS BEVACIZUMAB; EGFR MONOCLONAL-ANTIBODIES; KRAS MUTATIONAL STATUS; COLON-CANCER; V600E MUTATION; MICROSATELLITE INSTABILITY; 1ST-LINE TREATMENT; RAS MUTATIONS; POOR SURVIVAL; MAPK PATHWAY;

D O I：

10.2217/pgs.15.140

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

BRAF mutations are detectable in about 5-15% of metastatic colorectal cancer (mCRC) patients and represent a clear negative prognostic factor. While in BRAF-mutated (BRAFmt) metastatic melanoma TKI target therapies (BRAF and MEK inhibitor), both alone or in combination, have shown significant efficacy, in BRAFmt CRC single-agent BRAF-inhibitors as well as chemotherapy seem to be ineffective. The critical role of EGFR in CRC and its multiple downstreaming pathways seem to be involved in this lack of response. In recent years, preclinical investigations and retrospective studies slowly increased our knowledge on BRAFmt CRC. This review analyses preclinical data and discusses several clinical trials in order to explore new therapeutic strategies targeting BRAFmt mCRC.

引用

页码：2069 / 2081

页数：13

共 65 条

[61] Wang Qi, 2014, Chinese Medical Sciences Journal, V29, P197
[62] Pilot Trial of Combined BRAF and EGFR Inhibition in BRAF-Mutant Metastatic Colorectal Cancer Patients
Yaeger, Rona
Cercek, Andrea
O'Reilly, Eileen M.
Reidy, Diane L.
Kemeny, Nancy
Wolinsky, Tamar
Capanu, Marinela
Gollub, Marc J.
Rosen, Neal
Berger, Michael F.
Lacouture, Mario E.
Vakiani, Efsevia
Saltz, Leonard B.
[J]. CLINICAL CANCER RESEARCH, 2015, 21 (06) : 1313 - 1320
[63] The Prognostic Role of BRAF Mutation in Metastatic Colorectal Cancer Receiving Anti-EGFR Monoclonal Antibodies: A Meta-Analysis
Yuan, Zi-Xu
Wang, Xiao-Yan
Qin, Qi-Yuan
Chen, De-Feng
Zhong, Qing-Hua
Wang, Lei
Wang, Jian-Ping
[J]. PLOS ONE, 2013, 8 (06):
[64] Yuen ST, 2002, CANCER RES, V62, P6451
[65] Activation of B-Raf kinase requires phosphorylation of the conserved residues Thr598 and Ser601
Zhang, BH
Guan, KL
[J]. EMBO JOURNAL, 2000, 19 (20) : 5429 - 5439

← 1 2 3 4 5 6 7 →